Coverage Determination Request Form – Infusion / Injectable Drugs; Analgesic and Antispasmodic Therapy (Medicare B vs. D)

Request Information (required)

This request is:

- ☐ **Expedited* (Urgent)** (decision within 24 hours)
- ☐ **Standard (Non-Urgent)** (decision within 72 hours)

*If the requestor or prescriber believe that waiting 72 hours for a standard decision could seriously harm the member's life, health, or ability to regain maximum function, an expedited (fast) decision can be requested. If the prescriber indicates that waiting 72 hours could seriously harm the member's health, a decision will automatically be made within 24 hours. If the prescriber's support for an expedited request is not obtained, the request will be reviewed to determine if a fast decision is required.

Please Note: All information below is required to process this request. Any information that is incomplete or illegible will delay the review process. If the request is asking for an EXCEPTION, the prescriber MUST provide a statement supporting the request and the request cannot be processed without one. Please submit all **FORMULARY EXCEPTION** requests on the standard **CMS COVERAGE DETERMINATION** form. Requests that are subject to PRIOR AUTHORIZATION (or any other utilization management requirement), may require supporting information.

Member Information (required)			Prescriber Information (required)		
Member Name:			Prescriber Name:		
Member Insurance ID #:			NPI # :	Specialty:	
Date of Birth:			Office Phone:		
Member Phone:			Office Fax:		
Member Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:

Requestor Information (required if not requested by the member or prescriber)

An individual other than the member or prescriber (such as a family member or friend) may make a request on behalf of the member provided that the individual is a representative. **Documentation must be attached** showing the individual's authority to represent the member (a completed Authorization of Representation Form CMS-1696 or a written equivalent). For more information on appointing a representative, contact the plan or 1-800-Medicare.

Requestor Name:	Requestor Phone:	
Requestor Address:	Relationship to Member:	
City:	State:	Zip:

Medication Information (required)

Indicate Medication Requested: (NOTE: Drugs below are a representative list, only. See plan formulary to verify coverage status.)	Quantity Prescribed:	Dosage Form:
☐ morphine sulfate (ASTRAMORPH, DURAMORPH) ☐ hydromorphone hydrochloride (DILAUDID) ☐ ziconotide acetate injection (PRIALT) ☐ clonidine hydrochloride injection ☐ morphine sulfate for mircoinfusion injection (MITIGO) ☐ baclofen intrathecal injection (LIOREAL) ☐ baclofen intrathecal solution (GABLOFEN) ☐ Other: _____		
Strength & Route of Administration:	Directions for Use (including frequency and expected length of therapy):	

B vs. D Primary Billing Determination (required)

1. Please indicate how the medication is being administered:

☐ Narcotic analgesic or ziconotide administered via external infusion pump **(*Continue to Section A*)**

☐ Drug administered via implantable infusion pump ***(Continue to Section B)***

☐ Other: _____ (***Complete Part D Coverage Determination Criteria below)***

<u>Section A</u>:

1) Please indicate where the member resides:

☐ Nursing Facility/Long-Term Care ***(Complete Part D Coverage Determination Criteria below)***

☐ Home setting ***(Continue to question 2)***

NOTE: *LTC setting is defined as NCPDP Pt Residence Code = 3 or 9; all other codes are considered "Home" setting for BvD.*

2) Is the requested medication ziconotide injection?

☐ Yes ***(Continue to question 3)***

☐ No ***(Continue to question 5)***

3) Is ziconotide injection being administered intrathecally for the management of severe chronic pain?

☐ Yes ***(Continue to question 4)***

☐ No ***(Complete Part D Coverage Determination Criteria below)***

4) Is the member refractory to other treatment such as systemic analgesics, adjunctive therapies, or intrathecal morphine?

☐ Yes ***(Continue to question 8)***

☐ No ***(Complete Part D Coverage Determination Criteria below)***

5) Is the requested medication morphine injection?

☐ Yes ***(Continue to question 6)***

☐ No ***(Continue to question 7)***

6) Is morphine injection prescribed for the treatment of intractable pain caused by cancer?

☐ Yes ***(Bill to Medicare Part B)***

☐ No ***(Complete Part D Coverage Determination Criteria below)***

7) **Is the requested narcotic analgesic medication prescribed in place of morphine for intractable pain caused by cancer that has not responded to an adequate oral/transdermal therapeutic regimen and/or the member cannot tolerate oral/transdermal narcotic analgesics?**

☐ Yes ***(Continue to question 8)***

☐ No ***(Complete Part D Coverage Determination Criteria below)***

8) **Are ALL the following criteria met:**

☐ Parenteral administration of the drug in the home is reasonable and necessary

☐ An infusion pump is necessary to safely administer the drug

☐ The drug is administered by a prolonged infusion of at least 8 hours because of proven improved clinical efficacy

☐ The therapeutic regimen is proven or generally accepted to have significant advantages over intermittent bolus administration regimens or infusions lasting less than 8 hours

☐ Yes ***(Bill to Medicare Part B)***

☐ No ***(Continue to question 9)***

9) **Are ALL of the following criteria met:**

☐ Parenteral administration of the drug in the home is reasonable and necessary

☐ An infusion pump is necessary to safely administer the drug

☐ The drug is administered by intermittent infusion (each episode of infusion lasting less than 8 hours) which does not require the beneficiary to return to the practitioner's office prior to the beginning of each infusion

☐ Systemic toxicity or adverse effects of the drug are unavoidable without infusing it at a strictly controlled rate as indicated in the Physicians' Desk Reference, or the U.S. Pharmacopeia Drug Information

☐ Yes ***(Bill to Medicare Part B)***

☐ No ***(Complete Part D Coverage Determination Criteria below)***

Section B:

1) **Is the requested medication morphine injection?**

☐ Yes **(Continue to question 2)**

☐ No **(Continue to question 6)**

2) **Is the morphine injection being administered intrathecally for the treatment of severe chronic intractable pain of malignant or non-malignant origin?**

☐ Yes **(Continue to question 3)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

3) **Does the member have a life expectancy of at least 3 months?**

☐ Yes **(Continue to question 4)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

4) **Has the member been unresponsive to less invasive medical therapy such as systemic opioids including attempts to eliminate physical and behavioral abnormalities which may cause exaggerated reaction to pain?**

☐ Yes **(Continue to question 5)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

5) **Has a preliminary trial of intraspinal medication been undertaken with a temporary intrathecal or epidural catheter to substantiate adequately acceptable pain relief, degree of side effects (including effects on the activities of daily living), and patient acceptance?**

☐ Yes **(Bill to Medicare Part B)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

6) **Is the requested medication ziconotide injection?**

☐ Yes **(Continue to question 7)**

☐ No **(Continue to question 9)**

7) **Is ziconotide injection being administered intrathecally for the management of severe chronic pain?**

☐ Yes **(Continue to question 8)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

8) **Is the member refractory to other treatment such as systemic analgesics, adjunctive therapies, or intrathecal morphine?**

☐ Yes **(Bill to Medicare Part B)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

9) **Is the requested medication clonidine injection?**

☐ Yes **(Continue to question 10)**

☐ No **(Continue to question 11)**

10) **Is clonidine injection being administered epidurally in combination with opiates for the treatment of severe pain in a cancer patient that is not adequately relieved by opioid analgesics alone?**

☐ Yes **(Bill to Medicare Part B)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

11) **Is the requested medication baclofen injection?**

☐ Yes **(Continue to question 12)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

12) **Is baclofen injection being administered intrathecally to treat chronic intractable spasticity?**

☐ Yes **(Continue to question 13)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

13) **Has the member been unresponsive to or had intolerable side effects during at least a 6-week trial of non-invasive methods of spasm control (such as oral anti-spasmodic medications)?**

☐ Yes **(Continue to question 14)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

14) **Has the member responded favorably to a trial intrathecal dose of the requested medication prior to pump implantation?**

☐ Yes **(Bill to Medicare Part B)**

☐ No **(Complete Part D Coverage Determination Criteria below)**

Part D Coverage Determination Criteria (required)

The following requirements need to be met before this drug can be covered by the Part D plan. These requirements have been approved by the Centers for Medicare and Medicaid Services (CMS), but you may ask us for an exception if you believe one or more of these requirements should be waived.

Which condition is the drug being used for?

☐ Indicate diagnosis: _____ ICD-10 Code (s): _____

Please Note: If the condition being treated with the requested drug is a symptom e.g. anorexia, weight loss, shortness of breath, chest pain, nausea, etc., provide the diagnosis causing the symptom(s) if known. This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either:*

- Approved by the Food and Drug Administration (FDA) – that is, that the FDA has approved the drug for the diagnosis or condition for which it is being prescribed.
- Supported by any of the following reference books – American Hospital Formulary Service Drug Information, the DRUGDEX Information System, and/or the USPDI or its successor.

Are there any other comments, diagnoses, symptoms, medications tried or failed (including dates of drug trials and results of previous drug trials), drug allergies and/or any other pertinent information the physician feels is important to this review? ☐ Yes ☐ No (If yes, please explain below)

_____

_____

_____

Exception Requests (optional)

If the request is not for a prior authorization, please indicate the request type:

The prescriber **MUST** provide a statement supporting the request. Requests cannot be processed without one.

☐ The member has been using a drug that was previously included on the plan's list of covered drugs, but is being removed or was removed from the list during the plan year.

☐ The request is for an exception to the plan's limit on the number of pills (quantity limit) the member can receive so that the member can get the number of pills the prescriber prescribed.

☐ The drug plan charges a higher copayment for the drug the prescriber prescribed than it charges for another drug that treats the member's condition, and the member wants to pay the lower copayment.

☐ The member has been using a drug that was previously included on a lower copayment tier, but is being moved to or was moved to a higher copayment tier.

☐ The drug plan charged the member a higher copayment for a drug than it should have.

☐ The member wants to be reimbursed for a covered prescription drug that they paid for out of pocket.

Do you believe one or more of the prior authorization requirements should be waived? ☐ Yes ☐ No

If yes, you must provide a statement explaining the medical reason why the exception should be approved.

Would this medication likely be the most effective option for this member? ☐ Yes ☐ No (If yes, please explain below)

_____

_____

_____

Is the member currently being treated for the condition(s) requiring the requested drug? ☐ Yes ☐ No

(If yes, please explain the member's current drug regimen for the condition(s) below)

_____

_____

_____

If the member is currently using this medication, would changing the current regimen likely result in adverse effects for the member? ☐ Yes ☐ No (If yes, please explain below)

_____

_____

_____

Are there any concerns for a drug interaction with the addition of the requested drug to the member's current drug regimen? ☐ Yes ☐ No (If yes, please explain the benefits despite the noted concern and the monitoring plan to ensure safety below)

_____

_____

_____

Are there any FDA noted contraindications to the requested drug? ☐ Yes ☐ No (If yes, please explain the benefits despite the noted concern and the monitoring plan to ensure safety below)

_____

_____

_____

Submission Information (required)

Signature: _____ **Date:** _____

Please Note:

- This request may be denied or dismissed unless all required information is received.
- The prescriber's office will receive a response via fax.
- For urgent requests, please call the phone number listed below.
- For real time submission 24/7 please visit the secure prescriber portal on our plan's website for the appropriate form and instructions on how to submit your request.
- Requests can also be initiated via phone or the form may be sent via fax or mail:

Phone Number: (866) 270-3877
Fax Number: (855) 668-8552
Mailing Address: ATTN: PRIOR AUTHORIZATION
P.O. Box 1039
Appleton, WI 54912-1039

Authorization Period: 1 Year - subject to formulary change and member eligibility/place of residence.

PLEASE FAX COMPLETED FORM TO: 855-668-8552